Medacta Group SA · SIX:MOVE
Medacta Group SA — FY2022 Earnings Presentation
17 slides from Medacta Group SA's earnings presentation, Mar 17, 2023
Slide 1: FY 2022 Financial Results
FY 2022 FINANCIAL RESULTS 17 March 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the presentation does not purport to be comprehensive. Please refer to the Medacta 2022 Annual Report available on our website at
Slide 3: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer FY 2022 Financial Results
Slide 4: 2022 Key Financial Figures
2022 Key Financial Figures* * Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency", "EBITDA", "Adjusted EBITDA" or “CORE EBITDA”, "Free Cash Flow", “Adjusted Free Cash
Slide 5: FY 2022 Medacta's Achievements
FY 2022 Medacta’s Achievements ▪ Medacta’s 2022 revenue amount to Euro 437.1 million, equal to 20.4% growth at reported currency, or 15.0% growth at constant currency from 2021 ▪ Adjusted EBITDA grew to Euro 120.4 million, or 12.4%, corresponding to 27.6% margin (28.1% in constant currency) ▪ Profit
Slide 6: FY 2022 Revenue Bridge vs 2021 by Geographic Area
1 FY 2022 REVENUE BRIDGE VS 2021 BY GEOGRAPHIC AREA ▪ Europe: good performance in almost all the markets, based on new customer's acquisition, but also a high organic growth ▪ North America: slow down in H1 due to Covid, staffing shortages and, slower than expected new customers growth throughout th
Slide 7: FY 2022 Revenue Bridge vs 2021 by Product Line
1 FY 2022 REVENUE BRIDGE VS 2021 BY PRODUCT LINE ▪ Hip: growth driven by the AMIS® strategy. Increasing contribution from the P-Family and product range extension (SMS Collared) and Bikini technique. Results geographically driven by Europe ▪ Knee: overall good performance with Kinematic Alignment co
Slide 8: FY 2019-2022: True Revenue Growth
FY 2019-2022: TRUE REVENUE GROWTH (€m) 437 +36.9% c.c.1 311 (+40.7% reported) 2019 2022 Revenue in 2022 was up 36.9% c.c. from FY 2019, representing a CAGR2 of 11% c.c. Notes: 1. Definitions of Alternative Performance Measures may be found on Annual Report, available on our website: https://www.meda
Slide 9: Corrado Farsetta, Chief Financial Officer
CORRADO FARSETTA Chief Financial Officer FY 2022 Financial Results
Slide 10: FY 2022 P&L: Remarkable Profitability
FY 2022 P&L: Remarkable Profitability1 PROFIT & LOSS STATEMENT (€m) FY 2021 A % FY 2022 A % Revenues 363.1 100.0% 437.1 100.0% Cost of Sales (101.9) -28.1% (131.9) -30.2% GROSS PROFIT 261.2 71.9% 305.3 69.8% CORE R&D expenses (11.3) -3.1% (15.6) -3.6% CORE S&M expenses (132.6) -36.5% (159.6) -36.5%
Slide 11: FY 2022 Investments for Future Growth
FY 2022 Investments for Future Growth FY 2022 Investments €65.1m % of Revenues 14.9% 3 ▪ Investments in instruments and in the development of new implants and surgical instruments to feed new customers started in 2022 and sustain the future growth. 1 ▪ Other tangible investment includes EUR 4.8M 2 f
Slide 12: FY 2022 Positive Free Cash Flow despite significant Investments
FY 2022 Positive Free Cash Flow despite significant Investments to fund the Future Growth FREE CASH FLOW (€m) FY 2021 A FY 2022 A CASH FLOW FROM OPERATING ACTIVITIES 54.1 73.5 CASH FLOW FROM INVESTING ACTIVITIES (52.0) (65.1) FREE CASH FLOW 2.0 8.4 12
Slide 13: Net Financial Debt
Net Financial Debt 1,2 0.87x 0.93x (€M) Notes: 1. For a reconciliation of Alternative Performance Measures please refer to section headed “Alternative Performance Measures” of the annual report. The 2022 annual report is available at https://www.medacta.com/EN/financial-reports 13 2. Non-IFRS measur
Slide 14: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer FY 2022 Financial Results
Slide 15: 2023 Outlook
2023 Outlook1 ▪ We are targeting at constant currency revenue in the range of EUR 480 million to EUR 495 million, and Adjusted EBITDA Margin largely in line with 2022, subject to any unforeseen events. Notes: 1. All targets described in our outlook should be measured in constant currency. Please ref
Slide 16: Q&A FY 2022 Financial Results
Q&A FY 2022 Financial Results
Slide 17: Adedacta
Adedacta International